KR20210133241A - 뉴모시스티스 종 폐렴의 치료 또는 예방을 위한 트리테르페노이드 항진균제 - Google Patents

뉴모시스티스 종 폐렴의 치료 또는 예방을 위한 트리테르페노이드 항진균제 Download PDF

Info

Publication number
KR20210133241A
KR20210133241A KR1020217030157A KR20217030157A KR20210133241A KR 20210133241 A KR20210133241 A KR 20210133241A KR 1020217030157 A KR1020217030157 A KR 1020217030157A KR 20217030157 A KR20217030157 A KR 20217030157A KR 20210133241 A KR20210133241 A KR 20210133241A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
pneumocystis
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217030157A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 에이. 앙굴로 곤잘레스
스티븐 앤드류 바라트
Original Assignee
싸이넥시스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 싸이넥시스, 인크. filed Critical 싸이넥시스, 인크.
Publication of KR20210133241A publication Critical patent/KR20210133241A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020217030157A 2019-02-27 2020-02-25 뉴모시스티스 종 폐렴의 치료 또는 예방을 위한 트리테르페노이드 항진균제 Pending KR20210133241A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811456P 2019-02-27 2019-02-27
US62/811,456 2019-02-27
PCT/US2020/019724 WO2020176527A1 (en) 2019-02-27 2020-02-25 Triterpenoid antifungals for the treatment or prevention of pneumocystis spp. pneumonia

Publications (1)

Publication Number Publication Date
KR20210133241A true KR20210133241A (ko) 2021-11-05

Family

ID=70005768

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217030157A Pending KR20210133241A (ko) 2019-02-27 2020-02-25 뉴모시스티스 종 폐렴의 치료 또는 예방을 위한 트리테르페노이드 항진균제

Country Status (15)

Country Link
US (1) US12594266B2 (https=)
EP (1) EP3930716B1 (https=)
JP (1) JP7581219B2 (https=)
KR (1) KR20210133241A (https=)
CN (1) CN113631165A (https=)
AU (1) AU2020228036B2 (https=)
BR (1) BR112021016876A2 (https=)
CA (1) CA3131298A1 (https=)
EA (1) EA202192344A1 (https=)
ES (1) ES3055272T3 (https=)
IL (1) IL285839A (https=)
MA (1) MA55081A (https=)
MX (2) MX2021010311A (https=)
TW (1) TWI910099B (https=)
WO (1) WO2020176527A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166135A (en) * 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
DK173802B1 (da) * 1988-09-12 2001-11-05 Merck & Co Inc Præparat til behandling af Pneumocystis carinii infeksioner og anvendelse af et cyclohexapeptid til fremstilling af et lægemiddel mod Pneumocystis carinii infektioner
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
CN108883152A (zh) * 2016-01-08 2018-11-23 奇达拉治疗公司 防止和治疗肺孢子虫感染的方法
MA49889A (fr) * 2017-04-10 2020-06-24 Scynexis Inc Agents antifongiques utilisés en association
KR102807716B1 (ko) * 2017-08-04 2025-05-13 싸이넥시스, 인크. 산성 pH에서 증진된 활성을 갖는 항진균제

Also Published As

Publication number Publication date
MX2021010311A (es) 2022-01-04
JP2022523212A (ja) 2022-04-21
WO2020176527A1 (en) 2020-09-03
US12594266B2 (en) 2026-04-07
AU2020228036A1 (en) 2021-09-23
TWI910099B (zh) 2026-01-01
MA55081A (fr) 2022-01-05
JP7581219B2 (ja) 2024-11-12
AU2020228036B2 (en) 2025-08-07
EP3930716B1 (en) 2025-09-10
IL285839A (en) 2021-10-31
EP3930716A1 (en) 2022-01-05
CN113631165A (zh) 2021-11-09
BR112021016876A2 (pt) 2021-11-03
MX2025004197A (es) 2025-09-02
ES3055272T3 (en) 2026-02-10
CA3131298A1 (en) 2020-09-03
TW202045169A (zh) 2020-12-16
US20230149376A1 (en) 2023-05-18
EA202192344A1 (ru) 2021-11-15

Similar Documents

Publication Publication Date Title
US20260000656A1 (en) Antifungal agents with enhanced activity in acidic ph
US20250248983A1 (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
US12594266B2 (en) Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia
HK40066679A (en) Triterpenoid antifungals for the treatment of pneumocystis spp. pneumonia
HK40066679B (en) Triterpenoid antifungals for the treatment of pneumocystis spp. pneumonia
HK40091926A (en) Antifungal agents with enhanced activity in acidic ph
HK40062347A (en) Triterpenoid antifungals for the treatment or prevention of pneumocystis spp. pneumonia
HK40062374A (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40062374B (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40030410B (en) Antifungal agents with enhanced activity in acidic ph
HK40030410A (en) Antifungal agents with enhanced activity in acidic ph
EA047126B1 (ru) Противогрибковое средство для лечения или профилактики инфекции вульвовагинального кандидоза

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902